目的 探究注射用丹參多酚酸聯(lián)合瑞舒伐他汀用于急性缺血性腦卒中治療的效果及對脂蛋白相關磷脂酶A₂（Lp-PLA₂）、氧化修飾型低密度脂蛋白（ox-LDL）、白細胞介素-6（IL-6）表達的影響。方法 選擇2020年1月—2022年10月安陽市人民醫(yī)院收治的急性缺血性腦卒中患者200例為研究對象進行回顧性分析，根據(jù)治療方案不同將患者分為對照組和試驗組，每組各100例。對照組患者接受溶栓、常規(guī)對癥治療＋瑞舒伐他汀（晚飯后口服，每次10 mg，每天1次）；試驗組患者在對照組基礎上加用注射用丹參多酚酸，每次0.13 g，每天1次，用0.9%氯化鈉注射液250 mL稀釋，靜脈滴注。兩組均連續(xù)治療14 d。比較兩組臨床療效，比較治療前后兩組患者血清Lp-PLA₂、ox-LDL、IL-6水平及大腦中動脈（MCA）、大腦前動脈（ACA）、大腦后動脈（PCA）腦血流速度。觀察治療期間兩組不良反應發(fā)生情況。結果 試驗組治療總有效率為97.00%，較對照組89.00%顯著升高（P＜0.05）。治療前，兩組患者血清Lp-PLA₂、ox-LDL、IL-6水平及MCA、ACA、PCA腦血流速度比較，均無顯著差異（P＞0.05）。治療后，兩組血清Lp-PLA₂、ox-LDL、IL-6均較本組治療前顯著降低（P＜0.05），且試驗組低于對照組（P＜0.05）；治療后，兩組MCA、ACA、PCA腦血流速度均較本組治療前顯著升高（P＜0.05），且試驗組高于對照組（P＜0.05）；兩組不良反應發(fā)生率比較差異不顯著（P＞0.05）。結論 注射用丹參多酚酸聯(lián)合瑞舒伐他汀用于治療急性缺血性腦卒中，不僅可改善患者腦血流速度，調節(jié)Lp-PLA₂、ox-LDL、IL-6表達，還能提高整體療效，且安全性較高。

Objective To explore the effect of Salvianolic Acid for Injection combined with rosuvastatin in the treatment of acute ischemic stroke and its effect on the expression of lipoprotein related phospholipase A₂ (Lp-PLA₂), oxidized low-density lipoprotein (ox-LDL), and interleukin 6 (IL-6). Methods A total of 200 patients with acute ischemic stroke admitted to Anyang People's Hospital from January 2020 to October 2022 were selected for retrospective analysis. According to different treatment schemes, the patients were divided into control group and experimental group, with 100 cases in each group. The patients in the control group received thrombolysis, conventional symptomatic treatment+rosuvastatin (10 mg each time, once a day after dinner). The patients in the experimental group were added with Salvianolic Acid for Injection on the basis of the control group, 0.13 g each time, once a day, diluted with 250 mL of 0.9% Sodium Chloride Injection, and intravenous drip. Both groups were treated continuously for 14 days. The clinical efficacy of two groups was compared, and the serum levels of Lp-PLA₂, ox-LDL, IL-6, as well as the cerebral blood flow velocity of the middle cerebral artery (MCA), anterior cerebral artery (ACA), and posterior cerebral artery (PCA) were compared before and after treatment. The occurrence of adverse reactions in both groups were observed during the treatment period. Results The total effective rate of the experimental group was 97.00%, which was significantly higher than the control group's 89.00% (P＜0.05). Before treatment, there was no significant difference in the levels of serum Lp-PLA₂, ox-LDL, IL-6, cerebral blood flow velocity of MCA, ACA, and PCA between the two groups of patients (P＞0.05). After treatment, the serum levels of Lp-PLA₂, ox-LDL, and IL-6 in both groups were significantly reduced compared to before treatment in same group (P＜0.05), and the experimental group was lower than the control group (P＜0.05). After treatment, the cerebral blood flow velocity of MCA, ACA, and PCA in both groups significantly increased compared to before treatment in same group (P＜0.05), and the experimental group was higher than the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion The combination of Salvianolic Acid for Injection and rosuvastatin in the treatment of acute ischemic stroke can not only improve the cerebral blood flow velocity, regulate the expression of Lp-PLA₂, ox-LDL and IL-6, but also improve the overall efficacy and safety.

R971